Piramal Snaps Up Peptide API Specialist Hemmo

Bolsters CDMO Business In Deal Worth More Than $100m

Piramal has announced a $106m deal to take full ownership of peptide API specialist Hemmo Pharmaceuticals, expanding its CDMO capabilities.

API Wooden Blocks Graphs
Piramal Pharma Solutions will gain peptide API capabilities from Hemmo • Source: Shutterstock

Piramal Pharma Limited has announced that it will bolster its Piramal Pharma Solutions contract development and manufacturing organization by acquiring peptide active pharmaceutical ingredient specialist Hemmo Pharmaceuticals “for an upfront consideration of INR7.75bn ($106m) and earn-outs linked to achievement of milestones.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Emcure’s Subsidiary Tillomed Boosts Portfolio With $20m+ Manx Deal

 
• By 

The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.

Lupin Boosts UK Presence Through Renascience Acquisition

 
• By 

Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.

Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement

 
• By 

Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

 
• By 

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

More from Business

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Celltrion Unveils Strategy Amid Series Of Milestones

 
• By 

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.

Samsung Rolls Out Second US Soliris Biosimilar – At 30% WAC Discount

 
• By 

Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.